Cartesian Therapeutics News Today

Reinet Investments SCA / Key word(s): Quarter Results Consolidated audited financial results for the year ended 31 March 2024 and proposed dividend 28-May-2024 / 07:35 CET/CEST Release

Reinet Investments SCA / Key word: Quarter Results CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND 28-May-2024 / 07:35 CET/CEST Release of...

Reinet Investments SCA Key word Quarter Results CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31 MARCH 2024 AND PROPOSED DIVIDEND 28May2024 0735 CETCEST Release of an ad hoc announcement

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. HC Wainwright currently has a $54.00 target price on the stock. A number of other research firms have also issued reports on RNAC. Needham & Company LLC reaffirmed a buy rating and […]

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday, Benzinga reports. They currently have a $54.00 price target on the stock. Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a buy rating and set […]

HC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research note issued to investors on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Several other analysts also recently weighed in on the company. Needham & Company LLC restated a buy […]

HC Wainwright restated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $54.00 price objective on the stock. Other equities research analysts also recently issued reports about the stock. SVB Leerink assumed coverage on shares of Cartesian Therapeutics […]

The CAR T-cell therapy market for acute lymphoblastic leukemia is poised for substantial growth, driven by the anticipated launch of therapies such as OBECABTAGENE AUTOLEUCEL (OBE-CEL), UCART22

BioPharma

Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Stock analysts at Leerink Partnrs boosted their Q2 2024 earnings estimates for Cartesian Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.95) per share for the quarter, up from their prior […]